Lipocine, Inc. (LPCN) Stock Sinking in the Aftermarket, Here’s What you Should Know.

Lipocine, Inc. (LPCN) is an innovative clinical-stage biotherapeutics firm engaged in drug production for metabolic and endocrine disorders. The lead product candidates of the company include TLANDO for treating hypogonadism, LPCN 1144 in Phase 2 trials for treating non-cirrhotic NASH, TLANDO XR in Phase 2 trials as an oral testosterone product, LPCN 1148 for liver cirrhosis, LPCN 1154 for treating post-partum depression, and LPCN 1107 for preventing recurrent preterm birth.

Top 5 Tech Stocks to Buy in 2024

Don't let the chaos of rising interest rates, potential recession, tighter credit issues, higher oil prices, and incessant geopolitical issues chase you from the markets. Instead, just wait it out. With too much fear in the market, go bargain hunting with tech stocks. We have complied a report with the five of the best ways to profit within this industry. "Top 5 AI Stocks to Buy in 2024."

Click here to sign up for our free report & newsletter, plus bonus offer "Elon Musk just Tiggered a BOOM in These Stocks"


The price of LPCN stock during the regular trading on January 14, 2022, was $0.99 with a slight increase of 1.59%. At last check in the aftermarket, the stock was significantly down by 9.49%.

LPCN: Events and Happenings

On January 5, 2022, LPCN reported its abstracts for podium and poster presentations at NASH-TAG 2022 Conference held on January 6-8, 2022.  On December 22, 2021, LPCN reported the preliminary dosing for LPCN 1148 Phase 2 clinical trials for managing liver cirrhosis in patients that are on the liver transplant list. The primary endpoint topline outcomes are anticipated during the second half of 2022.

LPCN: Key Financials

On November 10, 2021, LPCN reported its financial results for the third quarter ended September 30, 2021. Some of the key updates are as follows.

Net Loss per Share

Basic and diluted net loss for Q3 2021 was $3.1 million or $0.03 per share as compared to the same period prior year when the net loss was $4.3 million, or $0.07 per share.

Revenue and Assets

Total revenue in the third quarter of 2021 was $0.05 million. Total current assets for Q3 2021 were $40.3 million.

On November 4, 2021, LPCN reported about the grant of Fast Track Designation for its LPCN 1144 by the FDA. It was studied for the Liver Fat intervention with oral Testosterone paired biopsy Phase 2 clinical trials in NASH patients. On November 1, 2021, LPCN reported about the selection of its three abstracts for poster presentations at the American Association for the Study of Liver Diseases’ 2021 Liver Meeting held on November 12-15, 2021.


LPCN stock is impacted by the global pandemic situation which halted the economic progress of different businesses. The company’s stock is 21% down compared to six months period and is also declining in the current aftermarket trading due to a hostile market environment which reduced the investor’s interest in the company’s policies. The analysts are of the view that the company should make solid investor-oriented strategies in the wake of the current market scenario.